Vor Biopharma Inc. (VOR): who owns it and who trades it
As of Nov 16, 2026, VOR insiders reported 16 open-market sales worth $49.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ra Capital Management, L.P. (Director), with $22.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vor Biopharma
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VOR
103 funds and institutions reported VOR shares worth $911M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is TCG Crossover Management, LLC with 11.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 5.67M | 11.61% | $104M | No change |
| FMR LLC (Fidelity) | 4.93M | 10.10% | $90.8M | +220% |
| Fcpm III Services B.v. | 4.12M | 8.43% | $75.8M | No change |
| BlackRock, Inc. | 3.47M | 7.10% | $63.8M | +336% |
| Venrock Adviser, LLC | 3.04M | 6.23% | $56M | No change |
| State Street Corp | 2.62M | 5.36% | $48.2M | +134% |
| Frazier Life Sciences Management, L.P. | 2.54M | 5.21% | $46.8M | No change |
| Ra Capital Management, L.P. | 2.40M | 4.92% | $44.2M | -56% |
| Vanguard Capital Management LLC | 2.08M | 4.27% | $38.4M | +45% |
| Caligan Partners LP | 1.93M | 3.94% | $35.4M | No change |
| Paradigm Biocapital Advisors LP | 1.75M | 3.58% | $32.2M | No change |
| Great Point Partners LLC | 1.70M | 3.48% | $31.3M | -3% |
| Nantahala Capital Management, LLC | 1.69M | 3.46% | $31.1M | New |
| Geode Capital Management, LLC | 1.06M | 2.18% | $19.6M | +210% |
| NEXTBio Capital Management LP | 889,164 | 1.82% | $16.4M | -11% |
| ADAR1 Capital Management, LLC | 680,626 | 1.39% | $12.5M | New |
| Logos Global Management LP | 650,000 | 1.33% | $12M | -13% |
| Rosalind Advisors, Inc. | 648,600 | 1.33% | $11.9M | -7% |
| Nan Fung Trinity (hk) Ltd | 646,550 | 1.32% | $11.9M | New |
| Braidwell LP | 573,104 | 1.17% | $10.6M | +23% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VOR insiders reported $0 of open-market purchases and $49.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Rajeev M. Shah +3 | 10% owner | Sale | 213 | $19.75 | $4.2K | Form 4 |
| Apr 22, 2026 | Rajeev M. Shah +3 | Director | Sale | 165,150 | $15.77 | $2.6M | Form 4 |
| Apr 20, 2026 | Ra Capital Management, L.P. +3 | Director | Sale | 171,963 | $15.77 | $2.7M | Form 4 |
| Apr 17, 2026 | Ra Capital Management, L.P. +3 | Director | Sale | 458,411 | $16.28 | $7.5M | Form 4 |
| Apr 15, 2026 | Ra Capital Management, L.P. +3 | Director | Sale | 53,644 | $16.01 | $859K | Form 4 |
| Apr 14, 2026 | Ra Capital Management, L.P. +3 | Director | Sale | 153,735 | $15.97 | $2.5M | Form 4 |
| Apr 13, 2026 | Ra Capital Management, L.P. +3 | Director | Sale | 530,610 | $16.15 | $8.6M | Form 4 |
| Apr 10, 2026 | Rajeev M. Shah +3 | Director | Sale | 828 | $15.75 | $13K | Form 4 |
| Apr 9, 2026 | Rajeev M. Shah +3 | Director | Sale | 135,201 | $16.59 | $2.2M | Form 4 |
| Apr 8, 2026 | Rajeev M. Shah +3 | Director | Sale | 130,862 | $16.91 | $2.2M | Form 4 |
| Apr 8, 2026 | Rajeev M. Shah +3 | Director | Sale | 353,242 | $16.32 | $5.8M | Form 4 |
| Apr 6, 2026 | Peter Kolchinsky +3 | Director | Sale | 44,728 | $17.31 | $774K | Form 4 |
| Apr 6, 2026 | Peter Kolchinsky +3 | Director | Sale | 6,775 | $18.50 | $125K | Form 4 |
| Apr 6, 2026 | Peter Kolchinsky +3 | Director | Sale | 537,754 | $16.51 | $8.9M | Form 4 |
| Apr 2, 2026 | Peter Kolchinsky +3 | Director | Sale | 1,525 | $19.06 | $29.1K | Form 4 |
| Apr 2, 2026 | Peter Kolchinsky +3 | Director | Sale | 258,475 | $18.23 | $4.7M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ra Capital Management, L.P. | Director, 10% owner | – | $22.1M | Apr 20, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | $14.5M | Apr 6, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | $12.8M | Jul 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VOR short interest
High short interest. 12.2% of VOR shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 63%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.50M VOR shares were sold short, 12.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 759,510 shares, buying them all back would take about 9.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.50M | 12.22% | +1% | 759,510 | 9.9 |
| Oct 15, 2026 | 7.45M | 12.58% | -5% | 830,455 | 9.0 |
| Sep 30, 2026 | 7.81M | 13.21% | -1% | 1.80M | 4.3 |
| Sep 15, 2026 | 7.90M | 13.36% | +3% | 710,546 | 11.1 |
| Aug 31, 2026 | 7.67M | 12.96% | +4% | 739,511 | 10.4 |
| Aug 14, 2026 | 7.35M | 12.42% | +1% | 747,112 | 9.8 |
| Jul 31, 2026 | 7.25M | 14.85% | -1% | 871,822 | 8.3 |
| Jul 15, 2026 | 7.29M | 14.92% | -6% | 1.67M | 4.4 |
| Jun 30, 2026 | 7.74M | 15.85% | +30% | 2.06M | 3.8 |
| Jun 15, 2026 | 5.95M | 12.18% | +24% | 834,099 | 7.1 |
| May 29, 2026 | 4.82M | 9.86% | +5% | 804,527 | 6.0 |
| May 15, 2026 | 4.60M | 9.41% | -7% | 873,880 | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Vor Biopharma company events
Vor Biopharma filed 8 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Jul 7, 2026.
- Jul 7, 2026LeadershipAndrew Levin, M.D., Ph.D., a member of the Board of Directors of Vor Biopharma Inc., delivered his notice of resignation, effective immediately. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 8, 2026AnnouncementShared information with investors. Filing
- Mar 27, 2026AgreementVor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares of the Company’s common stock, at a price per Share of $14.05, for… Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Jan 2, 2026LeadershipVor Biopharma Inc. entered into a separation agreement with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities. Filing
- Dec 18, 2025LeadershipSarah Reed, a member of the Company’s Board of Directors, delivered her notice of resignation to the Board, effective immediately. Filing
- Dec 9, 2025LeadershipThe board of directors of Vor Biopharma Inc. approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the Company’s common stock under the Company’s Amended and Restated 2021 Equity Incentive Plan and the Company’s 2023 Inducement Plan was… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Vor Biopharma financials
Famous investors that hold VOR
4 of the 50 well-known investors we track reported holding VOR in their latest 13F filing. The largest position is Israel Englander's, worth $18.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 991,532 | $18.9M | 0.0% | +132% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 497,989 | $9.5M | 0.0% | +210% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 343,037 | $6.5M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 27,468 | $524K | 0.0% | +40% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VOR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 4.6% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 4.6% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 10.7% |
| Nov 5, 2026 | FMR LLC | 13G/A | 10.7% |
Questions about Vor Biopharma Inc. (VOR) stock
Who owns the most VOR stock?
The largest reported owner of Vor Biopharma Inc. (VOR) is TCG Crossover Management, LLC, with 11.6% of the company. In total, 103 funds and institutions reported holding VOR at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are VOR insiders buying or selling?
In the last 12 months, VOR insiders reported no open-market purchases and 16 sales worth $49.4M. The latest trade was on Jul 16, 2026. See every trade.
What is the short interest in VOR?
As of Oct 30, 2026, 7.50M VOR shares were sold short, 12.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 759,510 shares, buying them all back would take about 9.9 trading days (days to cover). See the history.
Which famous investors hold VOR?
4 of the 50 well-known investors we track reported VOR in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $18.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.